# US 2025/0144020 A1 · Ultra-long floating hydrogel raft for prolonged gastric retention and applications requiring buoyancy with controlled-release

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144020 A1
- Document ID: US20250144020A1
- Status: Published application
- Kind: A1
- Application number: 18/837,816
- Filed: 2023-02-14
- Published: 2025-05-08
- Earliest claimed: 2022-02-18
- Assignees: Nanyang Technological University
- Applicants: Nanyang Technological University
- Inventors: Say Chye Joachim LOO; Kaarunya SAMPATHKUMAR; Guo Dong KWANG
- Web page: https://patentgrep.com/patent/US20250144020A1

## CPC

- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/0007: {Effervescent (A61K9/0065 takes precedence)}
- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61K 47/02: Inorganic compounds
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are a pharmaceutical flotation device suitable for extended release of a pharmaceutical product in a stomach of a subject, the flotation device comprising a polymeric matrix that comprises a first polymeric material, a second polymeric material, and a crosslinking agent, wherein the first polymeric material and the second polymeric material form a hydrogel network; and the crosslinking agent is configured to generate additional crosslinks in at least the first polymeric material upon exposure to an aqueous solution having a pH of from 1 to 5, and a method of forming the pharmaceutical flotation device.

## Claims

### Claim 1

A pharmaceutical flotation device suitable for extended release of a pharmaceutical product in a stomach of a subject, the flotation device comprising a polymeric matrix that comprises:
a first polymeric material;
a second polymeric material; and
a crosslinking agent, wherein:
the first polymeric material and the second polymeric material form a hydrogel network; and
the crosslinking agent is configured to generate additional crosslinks in at least the first polymeric material upon exposure to an aqueous solution having a pH of from 1 to 5.

### Claim 2 (depends on 1)

The pharmaceutical flotation device according to claim 1, wherein the pharmaceutical flotation device is provided in a first portion shaped as a hollow vessel and one or more second portions shaped as one or both of a cap and a plug, such that a pharmaceutical product can be deposited within the hollow vessel and sealed inside by the one or both of cap and plug.

### Claim 3 (depends on 1)

The pharmaceutical flotation device according to claim 1, wherein a pharmaceutical product is encapsulated within the polymeric matrix of the pharmaceutical flotation device.

### Claim 4 (depends on 1)

The pharmaceutical flotation device according to claim 1, wherein the polymeric matrix further comprises an oil.

### Claim 5 (depends on 1)

The pharmaceutical flotation device according to claim 1, wherein the first polymeric material is selected from one or more of the group consisting of a pectin, and an alginate.

### Claim 6 (depends on 1)

The pharmaceutical flotation device according to claim 1, wherein the second polymeric material is selected from one or more of the group consisting of resistant starch, kappa-carrageenan, agarose, iota-carrageenan, cellulose, methylcellulose, ethyl cellulose, and gelatine.

### Claim 7 (depends on 6)

The pharmaceutical flotation device according to claim 6,
wherein the second polymeric material is kappa-carrageenan.

### Claim 8 (depends on 1)

The pharmaceutical flotation device according to claim 1, wherein the crosslinking agent is a bivalent metal carbonate.

### Claim 9 (depends on 8)

The pharmaceutical flotation device according to claim 8, wherein the bivalent metal carbonate is CaCO3.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The pharmaceutical flotation device according to claim 1, wherein the polymeric matrix comprises:
sodium alginate;
kappa-carageenan; and
CaCO3, where
the wt:wt ratio of the sodium alginate:kappa-carageenan:CaCO3 is about 1:1:1.

### Claim 13 (depends on 2)

The pharmaceutical flotation device according to claim 2, as dependent upon claim 2, wherein the pharmaceutical flotation device further comprises a pharmaceutical product.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method of forming a pharmaceutical flotation device according to claim 1, the method comprising the steps of:
(a) providing a solution mixture comprising:
a first polymeric material;
a second polymeric material;
a crosslinking agent; and
water, where the first polymeric material and the second polymeric material interact to form a hydrogel network;
(b) placing the solution mixture into a mould, solidifying the solution mixture and removing the water to provide a pharmaceutical flotation device.

### Claim 17 (depends on 16)

The method according to claim 16, wherein step (b) is conducted using at least two moulds, so as to form a first portion shaped as a hollow vessel and one or more second portions shaped as one or both of a cap and a plug, such that a pharmaceutical product can be deposited within the hollow vessel and sealed inside by the one or both of cap an plug.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the solution mixture further comprises a pharmaceutical product.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the solution mixture further comprises an oil.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 16)

The method according to claim 16, wherein the crosslinking agent is a bivalent metal carbonate.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the bivalent metal carbonate is CaCO3.

### Claim 25

(canceled)

### Claim 26 (depends on 25)

The method according to claim 25, wherein the maximum concentration of each of the first polymeric material and the second polymeric material in the solution mixture is from 1 to 2 wt %/volume.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 18)

The method according to claim 18, as dependent upon claim 18, wherein the pharmaceutical product is in the form of: particles of one or more active pharmaceutical ingredients; particles of one or more active pharmaceutical ingredients and pharmaceutically acceptable excipients; a tableted formulation; a capsule formulation; drug-loaded microparticles; and drug-loaded fibre meshes.

### Claim 30

(canceled)

### Claim 31 (depends on 1)

A pharmaceutical formulation comprising a pharmaceutical flotation device according to claim 1 and a pharmaceutical product.

### Claim 32

(canceled)
